Systems pharmacology models are having an increasing impact on pharmaceutical research and development from preclinical through postapproval phases, including use in regulatory interactions. Given the wide diversity among the models and the contexts of use, a common but flexible strategy for model assessment is needed to enable the appropriate interpretation of model-based results. We present an approach to evaluate these models and discuss how it can be customized to available data and intended application.
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MODEL ASSESSMENT CONSIDERATIONS
A wide range of modeling approaches, including empirical, mechanistic pharmacokinetic/pharmacodynamic, and quantitative systems pharmacology (QSP), can be applied toward pharmaceutical research and development. The evaluation of these models is critical to understanding their strengths/limitations and interpreting model results. Assessment typically involves evaluating fits to observed data and testing predictive capabilities where possible. Pharmacokinetic/pharmacodynamic models are routinely evaluated by goodness-of-fit plots, predictive checks, and external validations focused on capturing output data under the premise of parsimony. 1 In contrast, QSP models focus on the representation of underlying biological systems and address questions that involve exploration of mechanism and extrapolation to novel scenarios. QSP models are thus frequently and by necessity complex and underconstrained, leading to confusion around how QSP models can be appropriately evaluated. 2 Previous QSP tutorials have presented considerations in planning, developing, qualifying, and applying systems models. 3, 4 Here, we focus on model assessment, defining four major assessment areas (biology, implementation, simulation, and robustness), and suggest activities that can be customized based on the context of the work, mapping these efforts to previously presented QSP workflow stages and qualification criteria ( Table 1) . We illustrate the tailored application of the assessment approach with two published models of cancer signaling.
BIOLOGICAL RELEVANCE
Assessment of the biological relevance is of critical importance in QSP, where utility requires that the biology included is appropriate to address the problem at hand and reflects relevant knowledge, data, and literature. Thus, literature support and input from biological and clinical experts are valuable in assessment. Mechanisms, hypotheses, behaviors, and phenotypes of interest should be articulated to ensure the adequacy of biological scope. QSP models typically include the representation of targets, drugs, biomarkers, and outcomes of interest. Although the scale, breadth, and depth of biological scope differ greatly among applications, a model should minimally include sufficient biological pathways to connect each target or drug to the relevant biomarkers and outcomes, potentially via intermediaries.
MODEL IMPLEMENTATION
Assessment of the model implementation involves evaluation of the mathematical formulation and quality checks on the accuracy and veracity of the model, its mathematical structure, the parameters, and their influence on model simulations. The choice of formalism must be consistent with the project goals. Ensuring that the implementation is technically accurate (e.g., correct coding, unit consistency) and appropriate for the mechanisms represented is also essential and may be required in regulatory submission. Once structure and implementation are confirmed, dynamical systems analyses can be used to explore inherent model dynamics and corresponding parameter ranges to assess their relevance. Although structural identifiability of model parameters can be difficult to assess or ensure, the impact of the parameters on the ability to reproduce critical behaviors can be determined via sensitivity analyses that determine how uncertainty in and variability around a given parameter set (local) or throughout parameter space (global) influence model outputs. Other approaches, such as Monte Carlo simulation, that explore model behavior under different parameterizations can also inform this question and ensure consistency with expectations. These methods are used to confirm the ability of the model to generate distinct qualitative features or phenotypes (e.g., ranges of treatment response, different dynamical signaling features) 5 or to highlight needed revision of the model biology or mathematics.
SIMULATION RESULTS
Assessment of simulation results gauges the qualitative and quantitative plausibility of model simulations with respect to data and biological understanding. Generally, during modeling, parameters are estimated such that model or subsystem outputs match a set of qualitative and/or quantitative criteria. Confirmation that the model satisfactorily recapitulates this training/calibration data is one critical step. However, confidence in model predictions further requires testing the model's ability to prospectively or retrospectively predict data or behaviors not used in model calibration. Ideally, these validation/test experiments should be orthogonal to the calibration data yet fall within the scope of the biology represented. When data are limited, alternative approaches such as leave-one-out cross-validation or iterative calibration, validation, and updating can be considered. Sensitivity analysis that demonstrates appropriate responses to parameter modification can also provide confidence in simulated or predicted behaviors. Where validation against data or other biological knowledge is not demonstrated, prospective simulations should be considered explorations, hypotheses, or "potential outcomes" rather than predictions. In such scenarios, modeling can still provide value by increasing mechanistic understanding, highlighting potential outcomes, and identifying or reducing uncertainties and risks in pharmaceutical research and development.
ROBUSTNESS OF RESULTS
Assessment of the robustness of results ties in many aspects of biology, implementation, and simulations to increase confidence in model-based insight and predictions, specifically their robustness to biological variability and uncertainty (alternate hypotheses or quantitative differences). This assessment focuses on the extent to which the impact of variability or uncertainty in topology or parameters has been considered in predictions and the extent to which variability in data is captured. This can be done through explicit simulation of alternate parameterizations ("virtual subjects") 4 or collections thereof that cover input and/or output uncertainty and variability. 4, 5 Note that exploration of parameter uncertainty helps address concerns related to parameter identifiabilty.
CONTEXT DEPENDENCE
The application of the model and the availability of data determine how and to what extent different assessment approaches are appropriate. Some applications (e.g., clinical trial design) require more robust assessment, whereas a more flexible approach may be sufficient for mechanistic exploration. Decisions with significant safety or financial implications also require more rigorous assessment, as do efforts where modeling is a primary driver for a decision, without parallel evidence. Abundant data enable separate calibration and validation data sets, whereas limited data may necessitate other approaches to testing the model and corresponding caution in interpretation of results. In addition, different mathematical formulations require different mathematical assessment techniques. Although context influences how and to what extent each major assessment area is addressed, all areas should be considered and discussed. Figure 1 shows how contextual considerations can influence the degree of rigor required in model assessment and indicates the different context surrounding example models of cancer signaling pathways. [6] [7] [8] [9] Here, we discuss how context influences model assessment for two of these studies. 6, 7 Context Many cancers display alterations in mitogen activated protein kinase (MAPK), PI3K, and other intracellular signaling pathways that promote tumor growth. Briefly, the canonical MAPK pathway proceeds from receptor engagement through RAS, RAF, MEK, and ERK phosphorylation to downstream effects on cell growth, survival, and protein translation. Kirouac et al. 6 modeled the MAPK pathway based on rich preclinical and limited clinical data to explore the potential utility of a novel ERK inhibitor, especially in the treatment of RAF-mutant BRAF V600E colorectal cancer, to support clinical strategy and ongoing phase I trials. Eduati et al. 7 modeled multiple signaling pathways, including MAPK, using in vitro data from a broad set of colorectal cancer lines to investigate diversity in cellular signaling and mechanisms of resistance and to suggest sensitivities for possible therapeutic investigation. Figure 1 Context-dependent considerations in assessment of Quantitative Systems Pharmacology models. The rigor required or flexibility acceptable in model assessment is influenced by context-specific considerations, including: intended application of the model; financial, safety, or other risks involved; parallel evidence supporting model-based recommendations; intended positioning of modeling work; and the nature and extent of the data available for the modeling effort. As illustration, we roughly indicate on the axes the different context of each of the following modeling efforts involving the mitogen-activated protein kinase (MAPK) signaling pathway: (1) Kirouac et al. 6 used preclinical and limited clinical data to support clinical strategy with potentially significant consequences and only preclinical parallel evidence on the drug/combo efficacy; (2) Eduati et al. 7 used rich preclinical data to explore signaling diversity and resistance mechanisms and propose hypotheses for in vitro testing; (3) different dynamical models 8, 9 have aimed more generally to understand the implications of mechanistic signaling topology and feedback on the pathway behavior. 
